Tabasi Zohreh, Mesdaghinia Elaheh, Abedzadeh-Kalahroudi Masoumeh, Sehat Mojtaba, Panahandeh Aida
Department of Obstetrics and Gynecology, Kashan University of Medical Sciences, Kashan, Iran.
Trauma Nursing Research Center, Kashan University of Medical Sciences, Kashan, Iran.
Obstet Gynecol Sci. 2020 May;63(3):261-269. doi: 10.5468/ogs.2020.63.3.261. Epub 2020 Mar 30.
This study aimed to compare the effects of vaginal misoprostol, laminaria, and extra-amniotic saline infusion (EASI) on cervical ripening.
This randomized controlled trial was conducted on 195 women with singleton pregnancies and unripe cervices. Participants were randomly allocated to 3, 65-person groups: a misoprostol, a laminaria, and an EASI group. The interventions in the misoprostol, laminaria, and EASI groups included a single 25-µg vaginal misoprostol suppository, an intracervical laminaria, and a transcervical Foley catheter, respectively. The groups were compared with each other regarding time intervals from labor induction to labor active phase and delivery, cervical dilation, Bishop scores 6 hours after induction, delivery type, length of hospital stay, and complications.
There were no significant differences among the groups regarding maternal ages, gestational ages, body mass indices, baseline cervical dilations, and Bishop scores (>0.05). Six hours after induction, the Bishop score and cervical dilation were significantly greater in the EASI group than in the other 2 groups (<0.001). Moreover, time intervals from labor induction to labor active phase and delivery in the EASI group were significantly short (<0.001). The rates of cesarean section, fetal distress, placental abruption, and meconium staining in the misoprostol group were significantly high (<0.05), and the length of hospital stay in the EASI group was significantly short (<0.001).
EASI is a safer and more effective method for cervical ripening. Considering its inexpensiveness, easy accessibility, and greater effectiveness, EASI is recommended for cervical ripening.
Iranian Center for Clinical Trials Identifier: IRCT20170513033941N39.
本研究旨在比较阴道米索前列醇、海藻棒和羊膜腔外生理盐水灌注(EASI)对宫颈成熟的影响。
本随机对照试验对195名单胎妊娠且宫颈未成熟的女性进行。参与者被随机分为3组,每组65人:米索前列醇组、海藻棒组和EASI组。米索前列醇组、海藻棒组和EASI组的干预措施分别为单次阴道给予25μg米索前列醇栓剂、宫颈内置海藻棒和经宫颈放置Foley导管。比较各组从引产至产程活跃期和分娩的时间间隔、宫颈扩张情况、引产6小时后的 Bishop评分、分娩方式、住院时间和并发症。
各组在产妇年龄、孕周、体重指数、基线宫颈扩张和 Bishop评分方面无显著差异(>0.05)。引产6小时后,EASI组的 Bishop评分和宫颈扩张显著高于其他两组(<0.001)。此外,EASI组从引产至产程活跃期和分娩的时间间隔显著缩短(<0.001)。米索前列醇组的剖宫产、胎儿窘迫、胎盘早剥和胎粪污染发生率显著较高(<0.05),EASI组的住院时间显著缩短(<0.001)。
EASI是一种更安全、有效的宫颈成熟方法。鉴于其成本低廉、易于获取且效果更佳,推荐使用EASI进行宫颈成熟。
伊朗临床试验中心标识符:IRCT20170513033941N39。